Skip to content
MarketScale
‹ Back to IndustriesHealthcare

How to Manage Revenue Losses Due to COVID-19 While Continuing to Supply Essential Community Services.

The most prominent topic in healthcare today is COVID-19. All healthcare areas felt the pandemic’s effects, and no practice was immune to the financial challenges resulting from the virus. Mary Tucker, CEO of UPIC Health, brought together a panel of healthcare experts to discuss these challenges and get some insights on how practices can…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share
How to Manage Revenue Losses Due to COVID-19 While Continuing to Supply Essential Community Services.

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Start free

The most prominent topic in healthcare today is COVID-19. All healthcare areas felt the pandemic’s effects, and no practice was immune to the financial challenges resulting from the virus.

Mary Tucker, CEO of UPIC Health, brought together a panel of healthcare experts to discuss these challenges and get some insights on how practices can manage to continue providing essential community services while battling the virus. Dr. Jamal Mahdavian, Solo Practitioner in General Surgeon, Health Alliance of the Hudson Valley in Kingston, NY, Dr. Gary Smalto, Vice President at Optum Advisory Services and Practice Partner Health System Performance Improvement, and Kevin Sexton, Managing Director of the Berkeley Research Group and retired CEO of Holy Cross Health, joined Tucker to talk about healthcare’s current state.

Sexton viewed the COVID-19 experience as a stress-test for the entire healthcare system.

“I would say there are three or four things we need to take a look at seriously going forward,” Sexton said.

He noted that, when the pandemic halted elective procedures during the spring, that placed a huge financial burden on the system and showed the healthcare industry’s fragility. The pandemic also uncovered the disparity in care for certain underserved groups in the United States.

“The net result was the system got in trouble, and we didn’t do a great job of delivering care and at least getting equal results for people in need,” he said.

Dr. Mahdavian pointed out that the United States’ employer-based insurance system also became an issue during the pandemic.

“As soon as you lost your job, you lost your insurance, at least within a certain amount of time. Most blue-collar jobs can’t be done from home,” Mahdavian said. “Even in the medical profession, itself, there is no ‘at home surgery.’”

“We’ve used our medical system as a way to treat case-by-case,” Dr. Smalto said. “And we really haven’t thought about covering populations. And what we’ve learned with COVID is that organizations, particularly healthcare systems that had risk contracts and populations under risk already, did better than organizations that primarily had fee for service. What that shows you is that fee for service is a risk model, and we didn’t know it.”

Follow us on social media for the latest updates in B2B!

Twitter – @MarketScale

Facebook – facebook.com/marketscale

LinkedIn – linkedin.com/company/marketscale

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free plan

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale workspace, up to 10 people
One professional video edit a month for qualifying companies
Media requests to your crowd, remote recording, AI writing tools
$0, no credit card, nothing that expires

More Healthcare Insights

NICE recommends Enhertu for HER2-low advanced breast cancer in England

NICE recommends Enhertu for HER2-low advanced breast cancer in England

American Pharmaceutical Review reported that NICE has recommended AstraZeneca and Daiichi Sankyo’s Enhertu for routine NHS use in people with HER2-low advanced breast cancer, following a commercial agreement and updates to NICE’s methods under the U.K.-U.S. Pharmaceutical Pricing Agreement.

  • 01NICE tied the reversal to 2026 changes: higher cost-effectiveness thresholds that took effect in April and a new quality-of-life assessment method published Aug. 27, 2026.
  • 02Access planning still varies by nation: Fierce Pharma reported Wales requires funding within 60 days of final guidance, while Scotland and Northern Ireland follow separate processes.

Sep 21, 2026

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly is investing $6.5 billion in a Houston manufacturing facility set to open around 2030, primarily to scale production of Foundayo, its oral GLP-1 treatment. The project signals a broader shift in U.S. pharmaceutical manufacturing reshoring and underscores the supply chain challenge of forecasting demand and building capacity years in advance for breakthrough therapeutics.

  • 01Eli Lilly commits $6.5 billion to a Houston pharmaceutical manufacturing facility due for completion around 2030, one of the largest single U.S. pharma production investments in recent years
  • 02GLP-1 demand forecasting remains highly uncertain: Lilly's CEO noted that one-third of new GLP-1 pill patients are now choosing Foundayo, illustrating fast-moving market share shifts that complicate production planning years in advance
  • 03Houston's selection reflects industrial capacity and workforce depth, positioning the region as a biomanufacturing corridor and creating long-term hiring demand in engineering, quality control, and skilled trades

Sep 21, 2026

Waiting for perfectly clean data is stalling healthcare AI, not protecting it

Healthcare organizations often delay AI initiatives waiting for perfectly clean data, but this assumption no longer holds: reliable subsets and synthetic data allow projects to start now while data work continues in parallel. Success requires starting with business outcomes rather than technology capabilities, and embedding governance in product strategy before implementation, not after.

  • 01Waiting for 100% clean data is effectively a decision never to start; hospital AI projects can begin on reliable data subsets while quality work continues in parallel.
  • 02Frame AI decisions around business outcomes (revenue growth, cost reduction, competitive advantage, new products, or ecosystem influence) rather than asking what AI can do.
  • 03Governance should be part of product strategy before design or purchase, especially as agentic AI takes actions—such as handling many revenue-cycle denials—while routing the rest to humans.

Sep 21, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512